Therapeutic targeting of acute lung injury and acute respiratory distress syndrome

详细信息    查看全文

• 作者：Theodore J. Standiford^a ; Peter A. Ward^b ; ^{pward@umich.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：AEC ; alveolar epithelial cell ; ALI ; acute lung injury ; ARDS ; acute respiratory distress syndrome ; BALF ; bronchoalveolar lavage fluid ; DAMPs ; danger-associated molecular patterns ; GM-CSF ; granulocyte-macrophage colony-stimulating factor ; IR ; ischemia-reperfusion ; LPS ; lipopolysaccharide ; NETs ; neutrophil extracellular traps ; PAMPs ; pathogen-associated molecular patterns ; PMNs ; polymorphonuclear leukocytes (neutrophils) ; TLRs ; toll-like receptors
• 刊名：Translational Research
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：167
• 期：1
• 页码：183-191
• 全文大小：525 K

文摘

There is no Food and Drug Administration-approved treatment for acute respiratory distress syndrome (ARDS), in spite of the relatively large number of patients with the diagnosis. In this report, we provide an overview of preclinical studies and a description of completed and future clinical trials in humans with ARDS. Preclinical studies dealing with acute lung injury have suggested roles for complement and complement receptors, as well as the evolving role of histones, but details of these pathways are inadequately understood. Anti-inflammatory interventions have not been convincingly effective. Various cell growth factors are being considered for clinical study. Interventions to block complement activation or its products are under consideration. Stem cell therapies have shown efficacy in preclinical studies, which have motivated phase I/II trials in humans with ARDS.